Breast cancer overall-survival can be predicted with a 19 lncRNA tissue signature

Objective: Studying the prognosis of breast cancer (BRCA) is of great significance for clinical treatment. LncRNA has been shown to be significantly important in breast cancer, but only few studies exist that relate to the prognosis of lncRNA. This study aimed to build a lncRNA-based breast cancer prognosis risk model using the data from TCGA datasets. Methods: we used the TCGA public database to explore the differential expression of lncRNA and cancer prognosis in breast cancer patients. The RNA-Seq data and clinical data pertaining to 1090 BRCA patients in the TCGA database were downloaded and analyzed. The prognosis-related lncRNAs in BRCA patients were identified in the training set and validated in the test set and the complete data set. ROC was performed to determine the optimal cut-off point for patient risk classification, and survival analysis was performed to determine its significance in prognosis prediction. Results: A total of 19 prognosis-associated differentially expressed lncRNAs (LSINCT5, TRG-AS1, CH17-189H20.1, RP11-1399P15.1, RP11-344P13.6, RP5-1028K7.2, AL022344.7, USP30-AS1, RP11-522I20.3, AL122127.25, BHLHE40-AS1, CHRM3-AS2, LINC00704, RP5-1073O3.2, RP11-316M21.6, CTA-384D8.31, RP11-10J5.1, RP11-426L16.3, RP11-344B5.2) were screened out. The BRCA prognosis risk assessment model based on 19-lncRNA can predict the survival rate of breast cancer patients. Conclusion: This model can predict the prognosis of breast cancer patients and these 19 lncRNAs can be used as potential molecular markers for breast cancer prognosis prediction.

Breast cancer; Long non-coding RNA; Prognosis; TCGA; Predicting model

[1] Tong CWS, Wu M, Cho WCS, To KKW. Recent advances in the treatment of breast cancer. Frontiers in Oncology. 2018; 8: 227.

[2] Brewster AM, Hortobagyi GN, Broglio KR, Kau SW, Santa-Maria CA, Arun B, et al. Residual risk of breast cancer recurrence 5 years after adjuvant therapy. Journal of the National Cancer Institute. 2008; 100: 1179–1183.

[3] Liu C, Jiang Y, Gu X, Xu Z, Ai L, Zhang H, et al. Predicting level 2 axillary lymph node metastasis in a Chinese breast cancer population post-neoadjuvant chemotherapy: development and assessment of a new predictive nomogram. Oncotarget. 2017; 8: 79147–79156.

[4] Arun G, Diermeier SD, Spector DL. Therapeutic targeting of long noncoding RNAs in cancer. Trends in Molecular Medicine. 2018; 24: 257–277.

[5] Quinn JJ, Chang HY. Unique features of long non-coding RNA biogenesis and function. Nature Reviews Genetics. 2016; 17: 47–62.

[6] Latgé G, Poulet C, Bours V, Josse C, Jerusalem G. Natural antisense transcripts: Molecular mechanisms and implications in breast cancers. International Journal of Molecular Sciences. 2018; 19: 123.

[7] Uszczynska-Ratajczak B, Lagarde J, Frankish A, Guigó R, Johnson R. Towards a complete map of the human long non-coding RNA transcriptome. Nature Reviews Genetics. 2018; 19: 535–548.

[8] Gutschner T, Richtig G, Haemmerle M, Pichler M. From biomarkers to therapeutic targetsthe promises and perils of long non-coding RNAs in cancer. Cancer and Metastasis Reviews. 2018; 37: 83–105.

[9] Reiche K, Kasack K, Schreiber S, Lüders T, Due EU, Naume B, et al. Long non-coding RNAs differentially expressed between normal versus primary breast tumor tissues disclose converse changes to breast cancer-related protein-coding genes. PLoS ONE. 2014; 9: e106076.

[10] Ding X, Zhu L, Ji T, Zhang X, Wang F, Gan S, et al. Long in-tergenic non-coding RNAs (LincRNAs) identified by RNA-seq in breast cancer. PLoS ONE. 2014; 9: e103270.

[11] Sørensen KP, Thomassen M, Tan Q, Bak M, Cold S, Burton M, et al. Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment. 2013; 142: 529–536.

[12] Hu P, Chu J, Wu Y, Sun L, Lv X, Zhu Y, et al. NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. Oncotarget. 2015; 6: 32410–32425.

[13] Xu S, Wang P, You Z, Meng H, Mu G, Bai X, et al. The long non-coding RNA EPB41L4a-as2 inhibits tumor proliferation and is associated with favorable prognoses in breast cancer and other solid tumors. Oncotarget. 2016; 7: 20704–20717.

[14] O’Quigley J, Moreau T. Cox’s regression model: computing a goodness of fit statistic. Computer Methods and Programs in Biomedicine. 1986; 22: 253–256.

[15] Renaud G, Stenzel U, Maricic T, Wiebe V, Kelso J. DeML: robust demultiplexing of Illumina sequences using a likelihood-based approach. Bioinformatics. 2015; 31: 770–772.

[16] Ge Y, Yan X, Jin Y, Yang X, Yu X, Zhou L, et al. fMiRNA-192 and miRNA-204 directly suppress lncRNA HOTTIP and interrupt GLS1-mediated glutaminolysis in hepatocellular carcinoma. PLOS Genetics. 2015; 11: e1005726.

[17] Mehta SL, Kim T, Vemuganti R. Long noncoding RNA FosDT promotes ischemic brain injury by interacting with REST-associated chromatin-modifying proteins. Journal of Neuroscience. 2015; 35: 16443–16449.

[18] Sahu A, Singhal U, Chinnaiyan AM. Long noncoding RNAs in cancer: from function to translation. Trends in Cancer. 2015; 1: 93–109.

[19] Liu H, Li J, Koirala P, Ding X, Chen B, Wang Y, et al. Long non-coding RNAs as prognostic markers in human breast cancer. Oncotarget. 2016; 7: 20584–20596.

[20] Tracy KM, Tye CE, Ghule PN, Malaby HLH, Stumpff J, Stein JL, et al. Mitotically-associated lncRNA (MANCR) affects genomic stability and cell division in aggressive breast cancer. Molecular Cancer Research. 2018; 16: 587–598.

[21] Lu W, Xu Y, Xu J, Wang Z, Ye G. Identification of differential expressed lncRNAs in human thyroid cancer by a genomewide analyses. Cancer Medicine. 2018; 7: 3935–3944.

[22] Horie M, Kaczkowski B, Ohshima M, Matsuzaki H, Noguchi S, Mikami Y, et al. Integrative CAGE and DNA methylation profiling identify epigenetically regulated genes in NSCLC. Molecular Cancer Research. 2017; 15: 1354–1365.

[23] Li J, Chen Z, Tian L, Zhou C, He MY, Gao Y, et al. LncRNA profile study reveals a three-lncRNA signature associated with the survival of patients with oesophageal squamous cell carcinoma. Gut. 2014; 63: 1700–1710.

[24] Iguchi T, Uchi R, Nambara S, Saito T, Komatsu H, Hirata H, et al. A long noncoding RNA, lncRNA-ATB, is involved in the progression and prognosis of colorectal cancer. Anticancer Research. 2015; 35: 1385.

[25] Zhou M, Zhao H, Wang Z, Cheng L, Yang L, Shi H, et al. Identifi-cation and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma. Journal of Experimental & Clinical Cancer Research. 2015; 34: 102.